Twist Bioscience (TWST)

• Market cap: $2.83B
• 1 day: 3.68%
• 5 days: 12.30%
• 1 month: -1.74%
• 3 months: 4.48%
• 6 months: -15.40%
• Year to date: 4.97%
• 1 year: 36.51%
• 5 years: 109.15%
• 10 years: 239.71%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

About: Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well-plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies and powers cost-effective, rapid high-throughput synthesis, enabling researchers to realize opportunities ahead rapidly. Geographically, it derives a majority of its revenue from the United States.

Employees: 923

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

193% more call options, than puts

Call options by funds: $5.94M | Put options by funds: $2.02M

17% more repeat investments, than reductions

Existing positions increased: 90 | Existing positions reduced: 77

3.67% less ownership

Funds ownership: 120.36% [Q2] → 116.69% (-3.67%) [Q3]

7% less funds holding

Funds holding: 261 [Q2] → 242 (-19) [Q3]

11% less capital invested

Capital invested by funds: $3.45B [Q2] → $3.09B (-$363M) [Q3]

32% less first-time investments, than exits

New positions opened: 34 | Existing positions closed: 50

50% less funds holding in top 10

Funds holding in top 10: 2 [Q2] → 1 (-1) [Q3]

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $48 1% upside
• Avg. target: $54 14% upside
• High target: $60 26% upside

5 analyst ratings

• positive: 5 100%
• neutral: 0 0%
• negative: 0 0%

Wolfe Research Doug Schenkel 20% 1-year accuracy 1 / 5 met price target	26% upside $60	Outperform Initiated	13 Dec 2024
TD Cowen Steven Mah 33% 1-year accuracy 2 / 6 met price target	22% upside $58	Buy Reiterated	26 Nov 2024
Barclays Luke Sergott 23% 1-year accuracy 11 / 48 met price target	9% upside $52	Overweight Maintained	19 Nov 2024
Scotiabank Sung Ji Nam 60% 1-year accuracy 12 / 20 met price target	14% upside $54	Sector Outperform Maintained	19 Nov 2024
Baird Catherine Ramsey 83% 1-year accuracy 10 / 12 met price target	1% upside $48	Outperform Maintained	19 Nov 2024